

**Australian Securities Exchange Limited  
Companies Announcements Office  
SYDNEY**

**7 February, 2012**

**Correction in relation to Chairman's Speech for General Meeting**

I wish to advise the market of a correction that is required to be made to the text of the speech given by me to shareholders of the Company at a meeting this morning, and a copy of which has been published on the Company's ASX platform.

Specifically, where I referred to Probiomics having:

- received valid acceptances under the Takeover Bid in respect of, inter alia, 76.94% of all Hunter Shares; and
- *in addition*, a relevant interest in 12.87% of Hunter Shares arising from a Pre-Bid Acceptance Agreement,

I should have advised the meeting that the 76.94% level of valid acceptances ***included*** the abovestated 12.87% relevant interest.

Accordingly, and for the sake of clarity, I advise that the total level of valid acceptances and relevant interest of Probiomics in Hunter Shares, as at close of business on 3 February, 2012, was 76.94%, and not 89.19%.

In addition, I advise that as at close of business on 6 February, 2012, the total level of valid acceptances and relevant interest of Probiomics in Hunter Shares was 79.11%.



**Patrick Ford**  
Non Executive Chairman

## **About Probiomics Limited**

Probiomics has proprietary ownership of a unique probiotic strain – PCC®

PCC® has been clinically proved to have superior qualities to other probiotic strains – particularly in promoting systemic immune response.

Probiomics' commercial objective is to earn royalties from licensing PCC® to distribution companies selling products in global markets.

## **CONTACTS**

Mr Ashok Jairath - Chief Financial Officer and Company Secretary

Tel: 02 9844 5422

Email [ashok.jairath@probiomics.com.au](mailto:ashok.jairath@probiomics.com.au)